

Scottish Chemo-Endocrine Trial D

Submission date 19/08/2002	Recruitment status No longer recruiting	☐ Prospectively registered ☐ Protocol
Registration date 19/08/2002	Overall study status Completed	☐ Statistical analysis plan ☐ Results
Last Edited 25/01/2019	Condition category Cancer	☐ Individual participant data ☐ Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr - -

Contact details

UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

Additional identifiers

ClinicalTrials.gov (NCT)

NCT00002579

Protocol serial number

SCTN-BR9403; EORTC 10901

Study information

Scientific Title

Tamoxifen following combination chemotherapy in treating women with operable invasive breast cancer

Study objectives

The aim of the trial is to assess whether adjuvant Tamoxifen given after post operative chemotherapy for primary breast cancer adds to the disease free at overall survival advantage which results from adjuvant chemotherapy alone. In Scotland, Tamoxifen will be given for 5 years whereas in other countries the duration will be 3 years. (Part of the Scottish Chemo-Endocrine Trial D (EORTC Trial 10901) - UK CCCR ABC trial framework)

As of 05/08/09 this record has been extensively updated. All updates can be found under the relevant field with the above update date. Please also note the start and end dates of this trial have been changed from 01/01/1999 and 15/05/1999 respectively. Funding information has been corrected from Scottish Therapy Network to Scottish Cancer Therapy Network.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Primary study design

Interventional

Study design

Randomised controlled trial

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Breast cancer

Interventions

Current information as of 05/08/09:

Patients are stratified by age and by participating institution. All patients undergo surgical resection with local radiation therapy, as appropriate. Within 4 weeks of surgery, patients receive cyclophosphamide, methotrexate, and fluorouracil (CMF) every 3 weeks for 6 courses. Radiotherapy is given within 4 weeks of completion of CMF. Before beginning the last course of CMF, patients are randomized to receive either oral tamoxifen daily for 5 years or no further therapy. Patients are followed every 6 months for 5 years, then yearly. Hormone therapy is prohibited except as specified above and except for short-term hormone replacement therapy for severe unresponsive menopausal symptoms.

Initial information at time of registration:

All patients receive chemotherapy, CMF (Cyclophosphamide, Methotrexate and 5-Fluorouracil) repeated every three weeks for six cycles.

Patients are then randomised to one of two treatment groups:

1. Group A: Tamoxifen, 20 mg daily for five years
2. Group B: No further treatment

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Tamoxifen, cyclophosphamide, methotrexate, and fluorouracil

Primary outcome(s)

(Added 05/08/09) Disease free at overall survival

Key secondary outcome(s)

Not provided at time of registration

Completion date

30/06/2004

Eligibility**Key inclusion criteria**

1. Pre- or post-menopausal
2. Histologically confirmed palpable unilateral invasive breast cancer of TNM (Tumour, Node, Metastasis) stages T1-T3, N0-N1 and M0, for whom adjuvant chemotherapy is considered an essential part of initial therapy
3. A bilateral mammography to have been performed within the year prior to randomisation

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

Female

Key exclusion criteria

1. Patients with in situ carcinoma only, including Paget's disease of the nipple without underlying invasion
2. Presence of distant metastases
3. Patients currently receiving tamoxifen
4. Prior history of other malignancy, other than adequately treated basal or squamous cell carcinoma of skin
5. Other contraindications to treatment

Date of first enrolment

01/07/1998

Date of final enrolment

30/06/2004

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

UKCCCR Register Co-ordinator

London

United Kingdom

NW1 2DA

Sponsor information

Organisation

Scottish Cancer Therapy Network (UK)

Funder(s)

Funder type

Other

Funder Name

Scottish Cancer Therapy Network (UK)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration